Loading...
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
The management of locally advanced head and neck squamous cell carcinoma (HNSCC) with Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), achieves only moderate response rates, and clinical trials that evaluated EGFR-blockade with tyrosine kinase inhibitors (TKI)...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6627901/ https://ncbi.nlm.nih.gov/pubmed/31181806 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060795 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|